Who
Reid M. Huber
Director
Company insider
Files Form 4 as: Director, Rapport Therapeutics; Director, CARGO Therapeutics; Director, Tango Therapeutics; Director, Bellicum Pharmaceuticals; EVP, Chief Scientific Officer, Incyte.
In numbers
- Trades disclosed
- 94
- Buys
- 1
- Sells
- 10
- Bought
- $499K
- Sold
- $9.6M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 12 Nov 2014
- Last trade
- 10 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 12 Sep 2025filed 15 Sep 2025 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Bought | $499K20,400 at $24.48 | filing |
| 19 Aug 2025filed 19 Aug 2025 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 18 Jun 2025filed 20 Jun 2025 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,850 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code A | —23,742 at $0.00 | filing |
| 9 Nov 2023filed 13 Nov 2023 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 3 Jan 2023filed 20 Jan 2023 | Bellicum Pharmaceuticals | SEC FORM 4 Code M | —80,968 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | Bellicum Pharmaceuticals | SEC FORM 4 Code M | —87,196 at $0.00 | filing |
| 1 Sep 2022filed 2 Sep 2022 | Bellicum Pharmaceuticals | SEC FORM 4 Code M | —46,489 at $0.00 | filing |
| 15 Jun 2022filed 16 Jun 2022 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 8 Jun 2022filed 28 Jun 2022 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Jan 2022filed 6 Jan 2022 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —19,494 at $0.00 | filing |
| 4 Jan 2022filed 6 Jan 2022 | Bellicum Pharmaceuticals | SEC FORM 4 Code M | —19,494 at $0.00 | filing |
| 15 Jun 2021filed 7 Jul 2021 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 4 Jan 2021filed 5 Jan 2021 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —19,494 at $0.00 | filing |
| 15 Jun 2020filed 16 Jun 2020 | Bellicum Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
News
Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 1,147 Shares of Company StockRAPP · themarketsdaily.com · 9 Oct 2026Recent Research Analysts' Ratings Changes for Rapport Therapeutics (RAPP)RAPP · dailypolitical.com · 8 Oct 2026Incyte (NASDAQ:INCY) & Agios Pharmaceuticals (NASDAQ:AGIO) Critical ContrastINCY · dailypolitical.com · 6 Oct 2026Vir Biotechnology (NASDAQ:VIR) & Incyte (NASDAQ:INCY) Critical ContrastINCY · dailypolitical.com · 5 Oct 2026
0 headlines in the last 90 days name Reid M. Huber; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.